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INTRODUCTION 
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coming events cast their shadow before                    
INTRODUCTION 
      
      Gestational hypertension is a multisystem disorder, affecting 
virtually every organ and system in the body.  Pre eclampsia denotes 
development of proteinuria >1+ along with gestational hypertension.  
Pre-eclampsia develops usually after 20 weeks of pregnancy.  It is a 
major cause of maternal, fetal, neonatal morbidity and mortality.  
       
      If we wish to prevent such disorder we must seek ways of 
preventing the disease process.  In preventing this disorder the most 
important limiting factor is lack of timely prediction. Several methods 
of identifying pregnant women who are at risk for pre eclampsia have 
been proposed.  These include the use of angiotension II pressor 
response, roll over test, the isometric hand grip exercise test and the 
mean arterial pressure test.  Many tests have limitations as screening 
tools in the clinical setting because of either their complexity, the high 
incidence of false positive results or the subjective nature of result 
interpretation.                           
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HCG has been acknowledged as hormone for years.  Recent studies 
have revealed its immunological role. Placental function changes in 
the form of increased Serum Beta HCG has been documented and 
several prospective studies showed changes in the hormone level 
which may present before the clinical diagnosis of pre-eclampsia.  
Many reasons have been postulated for suspecting the role of HCG in 
predicting immunological condition in obstetrics (Sayeed et al 1984). 
                            
         The purpose of this study is to determine whether elevated 
Serum Beta HCG in (early) second trimester in comparison with roll 
over test is a better predictor of Pre-eclampsia. 
REVIEW OF 
LITERATURE 
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REVIEW OF LITERATURE 
  
       Hypertensive disorders are the most common medical 
complications of pregnancy. Pre-eclampsia / Eclampsia have been 
recognized as clinical entity since the time of Hippocrates. 
             
        In 1916 zweiff first termed pre-eclampsia as “TOXEMIA” the 
disease of theories             
      
     Beverage wrote hat eclampsia was mentioned in the ancient 
Egyptian, Chinese, Indian and Greek literature. Probably the oldest 
reference is in the Atharva Vedha 200 BC. 
          
       Rossilin (1513) described convulsion as one of the ominous sign 
during pregnancy.  
        
      Bossier coined the word eclampsia differentiating eclampsia from 
epilepsy. 
       
      Lever (1843) discovered proteinuria in pre-eclampsia. 
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    The most common forms of hypertension are gestational 
hypertension which accounts for 70% of hypertension during pregnancy 
and pre-existing chronic hypertension which is responsible for most of 
the remaining cases.  
  
       Hypertensive disorders are associated with increased maternal and 
perinatal  mortality and present a wide spectrum of disorders, ranging 
from minimal elevation of blood pressure alone to severe hypertension 
with multiple organ dysfunction. 
 
Incidence and pre disposing factors 
              
      Incidence of pre eclampsia is commonly cited to be about 5% - 10%, 
although remarkable variations are reported.  According to Michael and 
Deswiet the incidence in primi, fluctuated between 3.0 to 13.7% since 
1950 epidemiology. .   
Incidence is influenced by parity, race, and genetic factors 
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Risk factors for Pre-eclampisa 
 Maternal factors: 
1.Primigravidity 
Mc.Gillivray in 1959 postulated that primigravidae are fifteen times 
more likely to develop proteinuria than parous women. 
 
2.Primi paternity 
 
    The first conception by the current partner causing pre-eclampsia is 
also a risk factor (Deswiet 2002).  
 
3. Short period of co habitation 
 
    Stable cohabitation with a single partner seems to reduce the risk of 
pre-eclampsia in the first pregnancy by that partner (Deswiet-2002). 
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4.Extremes of age. 
    
        Robillard and Halsey (1992) explained special predisposition to 
develop pre-eclampsia among teenage pregnant women.  The risk 
increases slightly with age, but is not affected by social class (Baird 
1977). 
 
5.Family history of preeclampsia 
 
The predisposition to pre-eclampsia is in part inherited (Chesley 
and Cooper) (1986), so that a positive family history is a risk factor 
(Cincotta and Brennecke 1998).  Daughters of eclamptic patients have a 
3% risk of developing pre-eclampsia (Johnstudd 14th edition) 
            
      However there is poor concordance between identical twin sisters 
(Thornton and Macdonald 1999) so that maternal genes are not a 
dominant factor.  
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6. Previous   preeclampsia 
 
The risk of recurrence varies from 1.9 to 24.9% (Johnstudd, 14th 
edition). 
 
7.Obesity 
 
Obese women are particularly susceptible (Sibai et al., 1997; Ros et 
al., 1998) although in one series of eclampsia the women tended to be 
under weight (Obesley 1984). 
      
       Obesity is associated with constellation of other medical problems 
including type II diabetes and hypertension (Syndrome X). The separate 
parts of this constellation of having all been associated with an 
increasing tendency to pre eclampsia (Kaaja et al., 1999) 
 
8.Medical disorders. 
 
i. Diabetes increased incidence of hypertensive disorder in pregnant 
diabetic females with combined incidence of 30%. 
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ii. Chronic Hypertension → Women with chronic hypertension are 3-
7 times more likely to develop higher blood pressure combined with 
proteinuria. 
iii. Chronic renal disease :Women having renal disease are more prone 
to develop hypertension,superimposed preeclampsia. 
iv. Migraine → pre-eclamptics had been repeatedly associated with 
the condition (Moox and Redman 1983; Marcoux et al., 1992). 
v. Antiphospholipid antibody syndrome and thrombophilia;  The 
association with APLA is strong (Branch et al., 1989).  Because of 
the very intense growth restriction that occurs it is said due to poor 
placentation. 
 
        Antiphospholipid antibodies are an acquired cause of 
thrombophilia.  This is a term used to describe a constitutional 
tendency to thrombo embolism some of which are genetically 
determined for example possession of factor V leiden gene or 
antithrombin III deficiency.  Thrombophilia is associated with more 
pregnancy complications and preinatal losses, including pre-
eclampsia (Kupfermine et al., 1999). 
Asthma: Recently asthma has also been identified as a risk factor 
(Demissic et al., 1998), although there is evidence that this may  
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be more associated with coincidental corticosteroid therapy than 
the disease itself (Schatz et al., 1997). 
      
9.Stressful Job 
 
         There are a number of reports (for example Klonoff Cohen et al.,           
1996) suggesting that stress at work may increase the risk of pre-          
eclampsia.   
 
PLACENTAL / FETAL FACTORS 
Considering pre-eclampsia is primarily a placental disease.  It is 
not suprising that placental or fetal factors may increase the risk. 
 
i. Advancing gestational age. 
ii. Poor placentation 
If it is considered that it is a separate condition that may or may 
not be associated with pre-eclampsia then it must be also 
considered to be a powerful predisposing factor (Redman et al., 
1999). 
iii. Multiple pregnancy (Mac. Gillivray 1959) 
iv. Placental hydrops (Jeffcoate and Scott, 1959) 
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v. Hydatiform mole (Chun et al., 1964)-onset<20 weeks. 
vi. Triploidy (Rijhsinghani et al., 1997) 
Trisomy-13 (Boyd et al., 1987) 
Trisomy-16 mosaicism (Brandenburg et al., 1996). 
 They all increase the risk by placental mechanisms presumably. 
vii. Polyhydramnios (Mac.Gillivray 1959). 
viii. Secondary sex ratio 
Butter observed an excess of male fetuses in Pre-eclampsia. 
 
GESTATIONAL HYPERTENSION 
 National high blood pressure education programme working 
group report on high blood pressure in pregnancy (2000) defines → 
Gestational hypertension as  
- Blood pressure > 140/90mm Hg for the first time during 
pregnancy. 
- No proteinuria 
- Blood pressure returns to normal < 12 weeks postpartum 
- Final diagnosis made only postpartum 
- May have other signs of pre-eclampsia, for example, epigastric 
discomfort or thrombocytopenia. 
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PRE-ECLAMPSIA – CRITERIA 
 
- Blood pressure of more than 140/90mm Hg after 20 weeks if 
gestation. 
- Proteinuria of more than 300mg in 24 hrs or more than 1 + 
dipstick. 
 
David K.James in his High risk pregnancy defines the criteria for severe 
pre-eclampsia as one or more of the following. 
 
-  Blood pressure reading with the patient at bed rest of atleast 
160/110mm Hg on two occasions atleast 6 hours apart. 
- Proteinuria levels of atleast 5g in 24 hours urine collection (or 3 + 
to 4 + on semiquantitative assay) 
- Oliguria: 24 hours urinary output of less than 400-500ml 
- Cerebral or visual disturbances – altered consciousness, 
headache, scotomata or blurred vision. 
- Pulmonary edema or cyanosis 
- Epigastric or right upper quadrant pain – caused by stretching of 
glisson’s capsule.  Occasionally the pain precedes hepatic 
rupture. 
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- Impaired liver function of unclear etiology. 
- Thrombocytopenia (Postulated to be caused by platelet adherence 
to collagen exposed at sites of disrupted vascular endothelium) 
below 1 lakh per cubic mm. 
- Intra uterine growth restriction or oligohydramnios with abnormal 
umbilical artery Doppler readings. 
- HELLP syndrome. 
 
Eclampsia - is the occurence of convulsions in a woman with 
pre-eclampsia.  Eclampsia was not differentiated from Epilepsy until 
1739. Ven De Sacevages wrote – all convulsions of acute causation as 
eclampsia. 
 
THEORIES OF CAUSATION OF PRE-ECLAMPSIA 
1.ENDOTHELIAL DYSFUNCTION 
 
Immunologically mediated deficiency in trophoblast invasion of 
placental bed spiral arterioles lead to poorly perfused fetoplacental unit.  
This leads to secretion of factors of vascular endothelium.  Damaged 
endothelium aggravates coagulation and increases sensitivity to 
vasopressor agents. 
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2.VASOACTIVE COMPOUNDS 
     
     A variety of cellular and serum vasoactive factors play a role in the 
etiology / pathogenesis of pre-eclampsia.  Endothelins are potent 
vasoconstrictors and Endothelin 1 produced by human endothelium is 
increased in pre-eclamptic females. [Clark 1992, Mastrogiannis 1991, 
Nover 1991, Schiff 1992].  Nitric oxide, a potent vasodilator synthesized 
by endothelial cells is shown to be decreased in preeclampsia (Chang 
and Colleagues in 1992). 
    
      Williams obstetrics twenty first edition published the study of 
Benedetto and associates (2000) that the Nitric oxide production 
appears to be increased in severe preeclampsia.  It appears to be a 
consequence of hypertension and not the inciting event (Morris and 
Colleagues, 1996). 
      In preeclampsia there is increased thromboxanes resulting in 
increased vasospasm and platelet destruction and increased lipid 
peroxide induced endothelial damage. 
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3.IMMUNOLOGICAL MECHANISM 
 
      Risk of preeclampsia is enchanced in circumstances where 
formation of blocking antibodies to antigenic sites in the placenta is 
impaired.  This may arise when numbers of antigenic sites are greater 
(Beer, 1978) or where immunization by previous pregnancy is lacking. 
 4.GENETIC PREDISPOSITION 
      
      Copper + Liston (1979) suggested that pre-eclampsia is dependent 
on single recessive gene.  Hayward and Co-workers (1992) reported an 
association between the histocompatibility antigen (HLA-DR 4) and 
proteinuric hypertension. 
 
Ward and lindheimer (2009) found that specifically seven out of 
70 genes found to closely related to development of pre-eclampsia genes 
for MTH FR, F5 (leiden), AGT, HLA (Various), NOS 3 (Glu 298 
ASP),Prothrombin Gene mutation20210A, (ACE I/D at intron 10) 
polymorphism causes pre-eclampsia. These are called as candidate 
genes. 
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5.INFLAMMATORY FACTORS 
    
       Cytokines, including tumour neurosis factor (TNF ) and the 
interleukins may contribute to the oxidative stress associated with pre-
eclampsia.In this scheme, oxygen free radicals lead to the formation of 
self-propagating lipid peroxides that in turn propagate highly toxic 
radicals, which inturn, injure endothelial cells. 
 
 
PATHOLOGY 
    
     Pre-eclampsia is defined as a two stage disorder.  According  to 
Redman and colleagues (2009) stage 1 is caused by endovascular 
trophoblastic remodeling that downstream causes the stage 2 clinical 
syndrome.  Importantly stage 2 is susceptible to modification by pre-
existing maternal conditions that include cardiac or renal disease, 
diabetes, obesity or hereditary influences (Williams obstetrics 23rd 
edition). 
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Abnormal trophoblastic invasion.  
                         
          In pre-eclampsia there may be incomplete 
trophoblasticinvasion,the deeper myometrial arterioles do not lose their 
endothelial lining and musculoelastic tissue and their mean external 
diameter is only half that of vessels in normal placentas (Fisher and 
colleagues 2009)and remain responsive to vasoconstrictor stimuli 
(Dixon and Robertson 1961, Broges et al., 1972, Roberston 1976). 
           Thus it is likely that the abnormally narrow arterioles impair 
placental flow.Diminished perfusion and a hypoxic environment 
eventually lead to release of placental debris that incites a systemic 
inflammatory response. 
(Redman and Sargent,2008) 
 
 ACUTE ATHEROSIS 
 
       In spiral arteries, accumulation of lipid in muscle cells in the media 
which are then taken up by macrophages to produce “Acute atherosis”.  
(Teek and Assali 1930).This leads to thrombosis and poor placental 
perfusion. 
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VASOSPASM   
     It is the basic factor in preeclampsia.  Hypoxia that results leads to 
the injury that releases thromboplastic substances by placenta into the 
blood steam which later leads to intravascular coagulation. 
 
 
 
Classification of hypertensive disorders in pregnant woman. 
 
1. Gestational hypertension 
2. Pre-eclampsia 
3. Eclampsia 
4. Chronic hypertension 
5. Super imposed pre-eclampsia on chronic hypertension 
 NORMAL                   PREECLAMPSIA 
Spiral 
arteries 
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PATHOPHYSIOLOGY OF PRE-ECLAMPSIA 
 
6.  
7.  
8.  
9.  
                                                      
 
 
 
 
         
      Oxygen free radicals,lipid peroxides 
 
 
 
 
 
                                                      Fibronectin  
                                                  e ndothelin, SFLT- endoglins 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Vascular 
endothelial cell 
dysfunction 
PLACENTAL 
ISCHAEMIA 
Prostacyclin 
deficiency 
↓Prostacylins 
 
Increased Thromboxances 
Loss of vascular smooth 
muscle hyporesponsiveness 
Persistent 
Vasoconstriction 
Reduced 
intravascular volume 
Hypertension 
Vascular endothelial 
cell damage 
Placental 
vascular 
abnormality 
Immunologic 
factors 
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MATERNAL AND FETAL COMPLICATIONS IN 
PREECLAMPSIA 
 
1. CARDIOVASCULAR CHANGES 
 
i. Increased arterial sensitivity to angiotensin II. 
ii. Increased pulse rate and hyperdynamic ventricular function. 
(Beneditti 1980, Hawkins 1984) 
iii. Increased blood pressure. 
iv. Decreased circulating blood volume and hemoconcentration. 
 
2.     RENAL SYSTEM 
 
i. Decreased renal perfusion and glomerular filtration rate. 
ii. Increased serum uric acid (Chesley and Williams 1945). 
iii. Serum Creatinine level is elevated two to three times. 
iv. Serum Sodium level is increased. 
v. Decreased urinary excretion of calcium due to increased 
tubular reabsorption. 
vi. Proteinuria develops later. 
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Albuminuria occurs due to increased permeability to large 
molecular weight proteins.  
vii. Histopathological lesion is glomerular capillary endotheliosis. 
 
3. LIVER 
  
      Derangement in hepatic function occurs.  Delayed excretion of 
Bromosulfothalein and increased SGOT (Serum Oxaloacetate glutamate 
Transaminase) and Serum Alkaline phosphatase occurs (Combes and 
Associates and Adam et al., 1972). 
  
     Hyperbilirubinimia is uncommon with Pedal edema (Pritchard in 
1976). 
 Anatomical lesion which is the periportal haemorrhagic necrosis 
in the periphery of the liver lobules leads to increased liver enzymes. 
 
4. COAGULATION SYSTEM 
i. Thrombocytopenia occurs in Preeclampsia (Leduc. 1992). 
Overt decrease to less than 1 lakh per micro litre is an 
ominous sign. 
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ii. Disseminated intravascular coagulation occurs. 
iii. Serum fibrin degradation products load increase. 
iv. Microangiopathic hemolysis occurs. 
v. Plasma fibrinogen does not differ unless some degree of 
placental abruption occurs. 
 
5. BRAIN 
i. Edema, hyperemia, thrombosis and haemorrhage occurs in 
association with pre-eclampsia. 
ii. Most women with varying degree of amaurosis are found to 
have extensive occipital lobe hypodensities with vasospasm 
of ophthalmic arteries (Williams 1992). 
6.HELLP SYNDROME 
 Liver involvement in pre-eclampsia is accompanied by hemolysis 
and thrombocytopenia. [De Boer 1991, Pritchard 1954, Weinstein 1985].  
It is associated with a high incidence of recurrent pre-eclampsia, pre-
term delivery, fetal growth restriction, placental abruption and caesarean 
deliveries. 
Diagnosis of HELLP syndrome 
1.Hemolysis 
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 Schistocyte in blood smear 
 Elevated Serum  indirect bilirubin  
 Absent plasma haptoglobin. 
2.Increased Liver enzymes 
Serum Oxaloacetate glutamate transaminase more than 72 IU/L. 
Lactate dehydrogenase more than 600IU/L. 
3.Decreased Platelet count 
Platelets less than 1 lakh per cubic milli liter.  
CLINICAL FEATURES 
      
       Most of the pregnant women are unaware of the two most important 
signs of pre-eclampsia, hypertension and proteinuria.  By the time the 
symptoms such as head-ache, visual disturbances or epigastric pain 
develop, the disorder is severe. 
SYMPTOMS 
Head-ache 
   
     Head-ache is often frontal but may be occipital.  It invariably precedes 
severe pre-eclampsia and may be a symptom of imminent eclampsia.  
The pain may be pulsatile or dull, may occur simultaneously with visual  
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symptoms and may frequently be intense, especially when preceding the 
onset of convulsions.  This may be due to cerebral artery vasospasm. 
 
Epigastric Pain 
  
    It is a symptom of severe pre-eclampsia and occurs due to 
hepatocellular necrosis,ischaemia,edema that stretches glisson’s capsule.  
This is accompanied by elevated liver enzymes in serum. 
 
Visual Disturbances 
  
      Visual disturbances are common with severe pre-eclampsia,. 
Retinal artery vasospasm may also be associated with visual 
disturbances (Ohno and Colleagues, 1999).Blindness can occur either 
alone or accompanies convulsion. 
 
Decreased urinary output 
Patient can have decreased urinary output. 
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SIGNS 
 
Blood pressure 
  
      Diastolic pressure is probably a more reliable prognostic sign than 
systolic blood pressure. 
           
       In severe pre-eclampsia the systolic blood pressure is more than 160 
mm Hg and the diastolic blood pressure is more than 110 mmHg. 
          
     Blood pressure should be taken in the sitting posture, with the 
apparatus at the level of the heart with appropriate size cuff.  Based on 
the recent evidence, the ISSHP (International society for the study of 
hypertension in pregnancy) has agreed that the Korotkoff V (K5) sound 
be used as a measure of diastolic blood pressure.  The K4/K5 difference 
is smaller in hypertensive than in normotensive pregnant women and K5 
is closer to the actual intra arterial pressure &is more reliably detected 
and is reproducible.  The universal adoption of K5 is recommended (John 
Studd 14th edition). 
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Proteinuria 
         
       It usually follows or appears simultaneously with hypertension and 
is non-selective.  Proteinuria is a valuable prognostic sign.  Frequent 
monitoring of the amount of protein excreted in the urine should be done 
and a significant increase in proteinuria indicates worsening of the 
disease. 
          
        Normal person excrete about 30-60 mg and even upto 200 mg of 
protein per day.  Proteinuria is the presence of urinary protein in 
concentrations greater than 0.3g in a 24 hrs collection (1 + or 2 + by  
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standard turbidimetric method) on two or more occasions at least 6 
hours apart.  The urine must be  a clean voided midstream specimen.  
Proteinuria may be the most ominous sign of pre-eclampsia. 
  
      A combination of 2+ (proteinuria) or 1g/litre and hypertension at 
least doubles the perinatal mortality rate. De Alvarez, (1976).  
Maccartney and Co-workers (1971) in their extensive experience studying 
renal biopsy specimens of hypertensive pregnant women invariably found 
that proteinuria was present ,when the glomerular lesion considered to 
be characteristic of pre-eclampsia was evident. (Glomerular 
endotheliosis). 
  
     Proteinuria may help us to differentiate eclamptogenic toxemia from 
other disorders of pregnancy.  In Orthostatic proteinuria, the commonly 
used 24 hours  urine sample demonstrates 1 or 2 mgs per 24 hours 
collection ,while the nephritic syndrome is indicated by a loss of 10 to 15 
gms/day.  The usual protein content in a 24 hours specimen is .03g to 2 
gms in pre-eclampsia. 
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Edema 
 
      It is the accumulation of fluid in the extra cellular spaces.  High 
oestrogen levels in pregnancy contribute to the generalized edema 
occurring in some pregnancies (Mudaliar and Menon, Ninth edition).  
Edema has been abandoned as a diagnostic criteria because it occurs in 
too many normal pregnant women to be discriminant. 
 
Fundus changes 
 
Grade 0   Normal fundus 
Grade 1 and 2   Arteriovenous narrowing  
Grade 3   Haemorrhage, exudates 
Grade 4   Papilledema 
 
COMPLICATIONS OF SEVERE PRE-ECLAMPSIA  
MATERNAL COMPLICATIONS 
1.Central Nervous System 
• Eclamptic Convulsions 
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• Cerebral haemorrhage 
• Cerebral edema 
• Cortical blindness 
2. Renal System 
• Renal cortical necrosis 
• Renal tubular necrosis 
3. Respiratory System  
• Laryngeal edema 
• Pulmonary edema 
 
4. Liver 
• Jaundice 
• Hepatic infarction 
• HELLP syndrome 
• Hepatic rupture 
5. Coagulation System 
• Disseminated intravascular coagulation 
• Microangiopathic hemolysis 
• HELLP syndrome 
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6. Placenta 
• Placental infarction 
• Retroplacental bleeding and Abruptio Placentae 
7. Eye 
• Papilledema 
• Cortical blindness 
• Retinal detachment 
Fetal Complications 
 
1.Intra uterine death – spasm of uteroplacental circulation leading to 
abruption and acute hypoxia. 
2.Intra uterine growth retardation due to placental insufficiency and 
chronic hypoxia. 
3.The fetus is often malnourished and small for gestational age (Moore 
and Redman, 1983) 
4.Iatrogenic Prematurity 
5.Birth Asphyxia. 
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SCREENING TESTS 
  
1.Estimation of Beta human chorionic gonadotrophin in (early) 
second trimester as a predictor for pre-eclampsia. 
 
 Serum Beta HCG shows as elevated level in mid trimester in 
patients prone to develop pre-eclampsia.  This may probably due to 
impaired placental function and a reflection of sub optimal utero 
placental blood flow.  Among all the predictor tests, a test which 
estimated BHCG will be a better marker since the pathophysiology of 
gestational hypertension is mainly due faulty placentation and reduced 
placental perfusion. 
 
 BHCG has now established its immunological role.  At the same 
time pre-eclampsia of early onset (<28 weeks of gestational age) is now 
accepted as having a strong immunological basis. Examination of serum 
BHCG at 16-20 weeks of gestational age will predict the pre-eclampsia.  
Explanation as to why BHCG may rise in gestational hypertension is  
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given by Heloner et al., (1996) who said that this rise was probably a 
secondary response of the trophoblasts to an immunological insult. 
 
Serum Beta Human chorionic gonadotrophin (BHCG) in normal 
pregnancy and in pre-eclampsia 
  
       BHCG is a pregnancy hormone.  It is a glycoprotein with biological 
activity similar to Leuteinising hormone (LH), both of which acts on the 
plasma membrane of LH/HCG receptor.  HCG is produced exclusively in 
the placenta, the detection of HCG in blood and urine is almost always 
indicative of pregnancy. 
 
Levels of BHCG in pregnancy 
  
       The hormone is produced exclusively by the 
syncytiotrophoblast.  As production begins very early in pregnancy 
certainly by the day of implantation, with the sensitive test it can be 
detected in maternal serum or urine by 8 to 9th day after conception.  
The doubling time of serum BHCG concentration is 1.4 to 2 days. It  
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reaches a peak at about 60-70 days.  Thereafter the concentration 
declines slowly until a nadir is reached at about 100-130 days. 
 
 
 HCG CURVE    IN NORMAL   PREGNANCY 
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HOW TO DETECT BHCG 
 
 Many different testing systems are available in kit form.Each is 
dependent upon the same principle, recognition of HCG (or a subunit) by 
an antibody to the HCG molecules or epitopes of the Beta subunit. 
            
          LH, TSH, BHCG have structurally similar (alpha) subunit.  But 
their beta subunit were structurally distinct. Specific antibodies were 
developed for beta subunit of BHCG to avoid cross reactivity against LH, 
TSH (thyroid stimulating hormone) immunoassay without radio isotopes. 
 
ELISA – Chemiluminescent immuno assay 
       
         It is useful for quantification of extremely small amount of 
hormones.  ELISA test uses monoclonal antibody bound to a solid phase 
support (usually plastic) which binds the HCG in the sample.  A second 
antibody is added to ‘sand wich’ the test sample HCG.  As it is the 
second antibody to which enzyme such as alkaline phosphatase is 
linked, when substrate for this enzyme is added, a blue colour develops, 
intensity of which is proportional to the amount of enzyme and thus to  
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the amount of second antibody bound.  This in turn indicates the 
quantity of HCG in the test sample.  The sensitivity of ELISA for BHCG is 
serum is 50 MIU/ML.  The method is said to be chemiluminescent assay. 
 
 
 
 
 
Sensitivity80% ,Specificity90% ,PPV75 ,NPV90. (Luckas et al study 1998) 
BHCG ANALYSER                                      ELISA  KIT 
35 
2.ROLL OVER TEST 
         
       Gant et al (1974) elicited marked pressor response by turning from 
lateral to supine recumbency in whom later developed pre-eclampsia.        
 
        This test done in pregnant women between 18-22 weeks of 
gestational age (Referral Iandonald’s – sixteenth edition).  
      
 The woman lay on left side,  blood pressure taken and then turned on 
their back,again blood pressure recorded.  The blood pressure was taken 
on one and five mintues interval after change in position.  The diastolic 
pressure rose by 20 mmHg in women who later developed pre-eclampsia.   
    
  This roll-over rest seems to have Sensitivity of 80% in predicting later 
pre-eclampsia, Positive predictive value is (PPV) 33%. 
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3.MIDTRIMESTER BLOODPRESSURE MEASUREMENT 
                      
       Blood pressure normally falls at the beginning of pregnancy and 
reaches its lowest level in the second trimester.  The use of mid trimester 
blood pressure recording as a screening test for pre-eclampsia is done 
during fifth and sixth month of gestation.  A mean arterial pressure 
(which is diastolic pressure plus one third of pulse pressure) of more 
than 90 mm hg increased the risk of gestational hypertension.  
Sensitivity 44%, specificity 87%, PPV 90%, NPV 98%, (Conde-Agudelo et 
al., 1993).  
  
ROLL OVER TEST  IN     LEFT LATERAL     AND     SUPINE      POSITION 
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        There are several factors which influence blood pressure 
measurement. The position of the arm relative to the heart also affects 
recording each centimeter of vertical height above or below the level of 
heart being equivalent to a difference of pressure .7 mm Hg. There is also 
variation of blood pressure with the circadian rhythm, values being 
highest during afternoon and early evening.  Also blood pressure is found 
to be elevated under stressful condition. For methods based on blood 
pressure measurements to be effective increased uniformity of recording 
measurement is necessary (Arias – third edition).  
4.HAND – GRIP TEST 
  
       Isometric exercise is known to cause a general sympathetic 
activation and to increase systemic arterial pressure in healthy adults.  
After a constant baseline diastolic blood pressure has been established, 
each of 100 subjects compressed an inflated sphygmomanometer cuff for 
a period of 3 minutes at maximal and then at 50% maximal voluntary 
contraction.  A rise of 20 mmHg in diastolic pressure was considered 
positive on 50% of maximal voluntary contraction.  This test is done 
between 28-32 weeks of gestation. Sensitivity 81.8%, Specificity (68.4%), 
but the test has poor reproducibility (Ian Donald 16th edition). 
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5.ANGIOTENSIN – II CHALLENGE TEST 
 
 This test is based on the loss of refractoriness to angiotensin II in 
pregnant woman who later develop pre-eclampsia.  In normal pregnancy, 
12 ng of angiotensin-II/kg per minute is needed to increase the diastolic 
pressure of at least 20 mm hg.  But woman prone to develop pre-
eclampsia needed only 8 ng angiotensin II/kg per minute to increase 
diastolic blood pressure. Sensitivity 91%.  However the test is expensive, 
time consuming and at times unreliable (Ian Donald’s 16th edition). 
 
6.DOPPLER ULTRA SOUND 
 
 In gestational hypertension, the physiological invasion of spiral 
arteries is incomplete.  Doppler wave forms appear to be abnormal in 
some hypertensive pregnancy.  Doppler velocimetry at 22-24 weeks is 
useful to identify women destined to develop pre-eclampsia, the 
sensitivity of a pulsablity index above the 95th percentile or the presence 
of bilateral notching with decreased diastolic flow in detecting women 
destined to develop pre-eclampsia with fetal growth restriction was 69%  
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and pre-eclampsia without fetal growth restriction was 24%.  The 
sensitivity increased to 93 and 80% respectively for woman developing 
severe forms of these complications requiring delivery before 32 
weeks.The positive likelihood ratio is 6.61. Though better test it can be 
confirmatory at 22-24 weeks only and Doppler ultrasound not available 
in every nook corner. (Arias 3rd edition) 
 
 
ROUTINE BLOOD TESTS 
 
SERUM URIC ACID 
  
        Serum uric acid levels is a better indicator of fetal prognosis than 
blood pressure. Serial  uric acid measurements gave warning of the 
disorder before the appearance of other clinical features in woman who 
subsequently develop gestational hypertension. 
 
PLATELET COUNT 
     Studies suggested that platelet count reduction occurred in pre-
eclampsia.(especially associated with HELLP) .  
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URINE ASSAYS 
 
        1.Urinary protein excretion normally increases in pregnancy and 
may occasionally rise to 200mg/24 hours, but it is usually undetectable 
by conventional laboratory test.  
           
      2. A study found that fasting urinary albumin creatinine ratio of 16 
or over was taken to indicate a positive screening test. 
     
    3.Another study found that microalbuminuria > 11 mg/ml as a 
positive test for predicting pre-eclampsia. 
      
   4. Urinary kallikrein to ,protein excretion ratio in a random sample 
collected at the booking visit (16-20 weeks) could be used to predict pre-
eclampsia.False positive rate 50%.False negative rate 10%. 
 There is difficulties in its assay. 
5..Urine calcium / creatinine ratio 
Determination of calcium/creatinine ratio in a randomly obtained 
urine sample ,if< 0.03 + 0.03 indicates women prone to develop pre- 
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eclampsia (Normal is 0.44 + 0.32) . PPV is 85%, NPV – 91%. (Arias 
3rd edition) 
 
 Other predictive tests for development of the pre-eclampsia  
syndrome (Adapted from conde-agudelo and associates 2009) 
 
 Testing related to Examples 
 
1. Placenta perfusion / 
vascular resistance 
24 hours ambulatory blood 
pressure monitoring. 
2. Fetoplacental unit 
endocrine dysfunction 
 Alpha feto protein, estriol, PAPP-
A, inhibin-A, activin-A.  
3. Renal dysfunction Microtransferrinuria, Nacetyl B 
glucosaminidase. 
4. Endothelial dysfunction / 
oxidant stress 
Fibronectin, prostaglandin, 
thromboxane, CRP, leptin, P-
selectin SF lt-1 (Fms like tyrosine 
kinase receptor-1.) 
5. Other / miscellaneous Antithrombin – III, atrial 
natriuritic peptide free fetal DNA, 
serum proteonomic markers ,B2 
micro globulin, genetic markers. 
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COMPARISON OF SENSITIVITY AND SPECIFICITY OF VARIOUS 
SCREENING TEST WITH BHCG ESTIMATION AND ROLL OVER TEST 
 
 
 
 
 
 
 
 
S. 
No 
NAME OF 
SCREENING 
TEST 
GESTATIONA
L AGE AT 
WHICH DONE 
 
SENSI
TIVIT
Y 
SPECI
FICIT
Y 
PPV NPV 
1. Mid trimester 
BP 
 
(20-22 wks) 44 87 90 98 
2. Hand grip 
test 
 
(28-32 wks) 81.8 68.4 81 96 
3. Doppler USG 
 (23-24 wks) 93 80 85 95 
4. Roll over test 
 18-22 wks 80 90 33 - 
5. BHCG 
 16-2o wks 80 90 75 90 
6. Urinary 
Calcium / 
creatinine 
ratio 
 70 91 85 91 
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PREVENTION OF PRE-ECLAMPSIA 
 
Primary prevention of Pre-eclampsia (Deswiet, fourth edition) 
 
 
 
Low-Dose Aspirin 
  
 The benefits of Aspirin (75mg OD) appear to be greatest in 
preventing early onset pre-eclampsia (relatively lesser) and least in 
preventing the disorder at term (which is common) (CLASP, 1994) 
 
 
Probably or definitely ineffective May be effective 
Weight restriction 
Salt restriction 
Diuretics 
Antihypertensive agents 
Calcium supplements 
Fish oil supplements 
Low dose aspirin 
Anti-oxidants 
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Antioxidants 
  
        Antioxidant therapy significantly reduced endothelial cell activation 
and there was a definite reduction in the incidence of pre-eclampsia in 
those women given Vitamin C and E (Chappel 1999). 
 
ANTI HYPERTENSIVE LINE OF MANAGEMENT 
 
 It is usually recommended when systolic blood pressure exceeds 
140 mm hg or diastolic blood pressure exceeds 90 mm hg.  Drugs widely 
used are methyldopa, nifedipine, labetalol, hydralazine. 
 
 
 
DRUG MODE OF ACTION PHARMACOLOGICAL 
ACTION 
DOSAGE ADVERSE 
EFFECT 
Methyldopa Induces the synthesis 
of alphamethyl nor 
epinephrine which 
stimulates alpha 
receptors and 
decreases the 
sympathetic outflow 
from the central 
nervous system. 
After3-6 hours of oral 
administration the 
hypotensive effect 
appears.  It causes 
decrease in cardiac 
output and total 
peripheral resistance. 
250mg tds,.. 
increased upto 
500mg tds. 
Sedation, fatigue, 
decrease in 
intellectual drive, 
drowsiness, fever, 
altered liver 
function test 
Nifedipine Calcium channel 
blocker (introduced in 
clinical practice by 
Flert eaten in 1970) 
Blocks calcium 
transport through its 
channel-inhibits the 
entry of extracellular 
ca 2+ necessary for 
excitation contraction 
so vasodilation of 
vessel, decrease in 
resistance. 
10mg tds Head ache, 
tachycardia, 
dizziness, fatigue, 
orthostatic 
hypotension.  
Labetalol Acts by decreasing  
peripheral vascular 
resistance.  It is both 
alpha and Beta 
receptor blocker. 
Rapid reduction of 
blood pressure. 
If given IV 20mg 
as initial dose, 
followed by 40-
80mg every 10 
minutes.  It can 
be given IV drop 
250mg in 250 
ml of NS and 
giving 20ml / 
minute.  
Contraindicated in 
congestive cardiac 
failure, bronchial 
asthma, can cause 
fatigue, insomnia, 
hypoglycemia. 
Hydralazine Vasodilator Rapidly lowers blood 
pressure, increases 
cardiac output and 
plasma volume. 
5-10mg IV that 
are repeated at 
10-20 min 
intervals. 
Head ache, 
anxiety, nausea, 
vomiting, facial 
flushing, SLE like 
syndrome in slow 
acetylators. 
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MANAGEMENT OF SEVERE PRE-ECLAMPSIA 
Definitive Management 
 Prevent convulsion (Magnesium sulfate) 
 Control blood pressure (Nifedipine) 
 Deliver by vaginal or caesarean birth (depending on fetal and 
maternal condition) having stabilized the maternal condition (if 
time permits) and obtained an update on renal, hepatic and 
hematologic status. 
 
Prevention of convulsions 
 Magnesium sulphate has been shown in randomized trials to be 
the preferred agent for prevention and treatment of eclamptic 
convulsions.  
          Intravenous loading dose of 4g results in immediate plasma 
concentration of 5-9mg/dl and it falls to 3-4mg/dl in 60 minutes.  It is 
excreted almost solely by kidney.  Then 4 gms in each buttock  I.M is 
given.  This is repeated every 4 hours. 
        Its action is to be mainly at peripheral neuromuscular transmitter 
junction with minimum central effects.  NMDA (N-methyl, D-aspartate) 
receptor is the excitatory aminoacid receptor subtype.  It is blocked by 
mg 2+ ions( cotton and associates1992) have shown that hippocampal  
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seizures could be blocked by magnesium.  Treatment should be 
continued upto 24 hours after the last convulsion or at least 24 hours 
post partum. 
 
Expectant management of severe pre-eclampsia less than 36 weeks 
(Arias 3rd edition – high risk pregnancy and delivery) 
 
- Bed rest 
- Daily weight 
- Antihypertensive treatment 
- Steriod for pulmonary maturity 
- RFT 
- LFT      Every other day 
- D-dimer evaluation 
- CBC 
- Daily questioning about head-aches, visual disturbances, 
epigastric pain and fetal movement. 
- Daily non-stress test. 
- Daily FKC 
- AFI every week. 
 
If gestational age more than 37 weeks, or those who develop 
complications, pregnancy is to be terminated with oxytocin or lower 
segment caesarean section 
Recurrence of pre-eclampsia in subsequent pregnancies 
Probability of recurrence is 30% 
 it depends on, 
a. At which gestation age previous pre-eclampsia developed 
 [ If - <30 weeks developed, recurrence is 70% 
 30-37 weeks – 40% 
 >37 weeks – 25% ] 
b. Multiparous (50% chance of developing hypertension in later 
pregnancies) 
c. Persistent hypertension for more than 10 days in the immediate 
post partum period 
d. Maternal obesity 
e. Severity of hypertension and symptoms 
f. Developing pre-eclampsia – later more prone to develop chronic 
hypertension (Pritchard & Pritchard 1977) 
g. If complicated by eclampsia in subsequent pregnancy development 
of 
Mild pre-eclampsia – 19.5% 
Severe pre-eclampsia – 25.9% 
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Recurrence of eclampsia – 1.4% can occur. 
33.8% had chronic hypertension (charley 1978) later in life. 
 
AIM OF THE STUDY
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AIM OF THE STUDY 
 
  
            The aim of this study is to compare the elevated serum beta 
human chorionic gonadotrophin in second trimester (16-20 weeks) with 
roll over test(18-22) in asymptomatic pregnant women to predict the 
development of pre-eclampsia. 
 
MATERIALS AND 
METHODS 
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MATERIALS AND METHODS 
 
This study was a prospective study.  
 This study was conducted at department of obstetrics, gynecology, 
RSRM lying in hospital attached to Stanley medical college from October 
2009 to October 2010. 
 150 normal pregnant women between 16 and 22 weeks of gestation who 
come to antenatal   O.P ,under gone both the tests. 
 
a. Serum BHCG estimation done between 16-20 weeks and 
b. Roll over test done between 18-22 weeks 
 
Exclusion criteria for the study were 
 
1. Multiple gestation 
2. Diabetes mellitus 
3. Previous h/o chronic hypertension 
4. Renal disease 
5. Congenital anomalies of the baby 
6. previous h/o pre-eclampsia / still births / repeated abortions, 
elderly primi 
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For BHCG estimation 
       5ml of blood collected from the women between 16-20 weeks of 
gestation and sent to thyrocare lab. There by enzyme linked 
chemiluminescent immuno assay method, they quantified the BHCG 
level.  If BHCG >2 M.O.M for the gestational age it predicts development 
of pre-eclampsia later. 
 
Reference Range of BHCG 
GESTATIONAL 
WEEKS 
                      BHCG RANGE 
1 -2                    10  -     94 MIU/ml 
2 -3                   61  -2922     
3 -4                    66  -18900 
4 -5                   1536  -49380 
6- 7                   13860  -90600 
7 -11                    12540  -174600 
11 -16                   3684  -61800 
16 -20                 2882  -48060(median value25100) 
21 -39                  1620  -46860 
Nonpregnant <        10MIU/ML 
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 For roll over  
   
The same women first in supine position in the right arm blood pressure 
measured.Then the women lies on left lateral position after 5 minutes 
and again blood pressure checked. 
 
If diastolic pressure rise by 20 mm Hg the test said to be positive which 
indicates she may develop preeclampsia later.      
 
RESULTS AND 
ANALYSIS
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RESULTS 
The incidence of preeclampsia in RSRM since 2005 varied between 
8.5%-10.2%. 
Between 2009 March-2010 March-Total number deliveries 12738,   
                                                     PIH cases                        1224 
                                                 the incidence is                    9.6%. 
The sample size is 150.Patients enrolled were 150. 
 Among 150 persons, (After excluding 4 persons due to non-compliance 
2,developed GDM 2 )rest 146 persons followed up.  
  Among 146 persons, 20 developed pre-eclampsia. 
  The incidence of pre-eclampsia in the study is 13.6%. 
 15 were primi and 5 were multi. 
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TABLE – 1 
DISTRIBUTION OF PATIENTS WITH PRE-ECLAMPSIA ACCORDING 
TO AGE 
 
  
 
 
          Above table shows the distribution of person with pre-eclampsia.  
Pre-eclampisa was high between 17-20 yrs (23%) and 31-34 years(26%). 
 
Age 
Study group 
Total No 
Pre-eclampsia 
Positive (%) 
17 – 20 34             8(23%) 
21 – 25 47 3(6.4%) 
26 – 30 42 3(7.1%) 
31 – 34 23 6(26%) 
Total 146            20 
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TABLE –2  
DISTRIBUTION OF PATIENTS WITHI PRE-ECLAMPSIA ACCORDING 
TO PARITY 
 
  
 
        
 Above table shows the distribution of patients with pre-eclampsia 
according to parity.  It shows high incidence of pre-eclampsia in 
primiparous women (75%) than in multiparous women. 
             Among 86 primi ,15 developed preeclampsia.the incidence is 
17.4% and 8.3% for multi in my study. 
 
PARITY TOTAL PRE-ECLAMPSIA 
POSITIVE 
% 
Primipara 86 15 75% 
Multiparous 60 5 25% 
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TABLE - 3 
 
DISTRIBUTION OF PRE-ECLAMPSIA PATIENTS ACCORDING TO 
THEIR FIRST APPEARANCE OF PRE-ECLAMPSIA (IN WEEKS). 
 
 
 
 
 
The above table shows highest incidence of pre-eclampsia 
between 36-40 weeks of gestation. 
Gestational age in weeks No   of patients 
20   -24        2 
24   -28       2 
28   -32       2 
32   -36       4 
36   -40      10 
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TABLE – 4 
RELATIONSHIP OF BHCG >2 M.O.M AND DEVELOPMENT OF PRE-
ECLAMPSIA 
 
Group 
(BHCG) 
Pre-eclampsia 
Positive 
Pre-eclampsia 
Negative 
No % No % 
> 2 MOM 
n = 22 
18 81.8% 4 18.2% 
< 2 MOM 
n = 124 
2 1.6% 122 98.4% 
 
 
Above table shows the relationship of BHCG >2 MOM developing 
pre-eclampsia. About 81.8%(PPV) of persons with BHCG >2 MOM 
develop pre-eclampsia. 98.4%(NPV) of person with BHCG <2 MOM does 
not develop pre-eclampsia. 
Out of 20 preeclampsia patients, with BHCG >2MOM 18 developed 
preeclampsia with           Sensitivity of 90%, 
                                   Specificity of 96.8%. 
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TABLE – 5 
 
RELATIONSHIP OF ROLL OVER TEST AND DEVELOPMENT OF PRE-
ECLAMPSIA 
Roll over test group 
Pre-eclampsia 
Positive 
Pre-eclampsia 
Negative 
No % No % 
Roll over test positive n = 28 14 50% 14 50 
Roll over test negative n = 118 6 6% 102 94% 
 
 
Above table shows the relationship of roll over test positive 
persons developing pre-eclampsia.  
About 50%(PPV) of persons with roll over test posistive develop 
pre-eclampsia. 94% (NPV)of persons with roll over test negative does not 
develop pre-eclampsia. 
  
Among 20 preeclampsia patients,14 with roll over test positive 
developed the disease with       Sensitivity 70%, 
                                Specificity 86.6% 
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TABLE – 6 
RELATIONSHIP OF BOTH BHCG > 2 MOM + ROLL OVER TEST 
POSITIVE GROUP WITH DEVELOPMENT OF PRE-ECLAMPSIA 
 
 
Above table shows development of pre-eclampsia when both tests are 
positive. 
 85.7% of persons with both test positive developed pre-eclampsia. 
Both 
tests 
positive 
Pre-eclampsia positive Pre-eclampsia negative 
No % No % 
n= 14 12 85.7% 2 14.3% 
 
TABLE - 7  
RELATIONSHIP OF BOTH ( BHCG  & ROLL OVER TEST) 
NEGATIVE BUT DEVELOPED PRE-ECLAMPSIA 
Both tests 
Negative 
Pre-eclampsia positive Pre-eclampsia negative 
No % No % 
110 2 1.8% 108 98.2% 
 
Above table shows development of pre-eclampsia when both tests 
were negative only 1.8% of persons with both tests negative developed 
pre-eclampsia 
TABLE - 8 
Distribution of persons developed pre-eclampsia in relation to 
parity with BHCG > 2 MOM 
Parity 
BHCG > 2 MOM 
No % 
Primipara n=15 15 100% 
Multipara n=5 3 60% 
 
Above table shows that 100% of primipara with BHCG > 2 MOM 
developed pre-eclampsia, but 60% of multipara with BHCG > 2 MOM 
developed pre-eclampsia. This shows BHCG has increased sensititivy to 
predict nullipara pre-eclampsia. 
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TABLE - 9  
DISTRIBUTION OF PATIENTS WITH PRE-ECLAMPSIA ACCORDING 
TO INITIAL BODY MASS INDEX (BMI) AND BHCG ELEVATION 
 
INITIAI BMI TOTAL PREECLAMPSIA 
PPSITIVE 
BHCG>2MOM 
19-25 66 4 2 
26-27 39 6 6 
28-30 36 6 6 
>30 5 4 4 
 
 
Above table shows that BMI > 25 is associated with BHCG > 2 
MOM and increased development of pre-eclampsia. 
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TABLE - 10 
 
DISTRIBUTION OF PERSONS DEVELOPED EARLY ONSET PRE-
ECLAMPSIA PREDICTED BY ROLL OVER TEST POSITIVE GROUP & 
BHCG > 2 MOM GROUP. 
 
 
Above table shows that 75% of persons with early onset pre-
eclampsia had BHCG > 2 MOM, but 25% persons had roll over test 
positive. 
EARLY ONSET 
PRE-
ECLAMPSIA 
ROLL OVER TEST 
POSITIVE 
BHCG > 2 MOM 
No % No 75% 
N=4 1 25% 3 75% 
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TABLE - 11 
RELATIONSHIP OF BHCG > 2 MOM AND DEVELOPING PRE-
ECLAMPSIA WITH INTRAUTERINE GROWTH RETARDATION (IUGR) 
 
 
 
 
 
100% of IUGR women had BHCG>2MOM and 
BHCG is highly predictive of severe preeclampsia with IUGR 
 
Total No 
BHCG > 2 MOM Roll over Positive 
No % No % 
3 3 100% 1 25% 
DISCUSSION
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DISCUSSION 
 
 
Study Comprised of 150 asymptomatic pregnant who undergone 
both serum BHCG estimation and roll over test between 16-20 weeks 
and 18-22 weeks of gestational age respectively.  
 Among them 4 women excluded due non-compliance and 
development of gestational diabetics mellitus. 
 But women with history of chronic hypertension, family history of 
hypertension, diabetes, renal disease, elderly primi, previous obstetric 
history with still birth & pre-eclampsia, abruption, intrauterine fetal 
death, congenitally anomalous baby were excluded.  These have been 
excluded because of their influence with BHCG estimation.  BHCG 
estimation done by chemiluminiscent immuno assay method. 
 
INCIDENCE 
Out of 146 patients, 20 developed pre eclampsia with incidence 
of13.6% who were diagnosed with high blood pressure and proteinuria. 
Rodriquez et al (1988) have reported an incidence of 10% . RituKamra et 
al 1997 has reported an incidence of 13.8%. 
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AGE DISTRIBUTION  
          In this study, most of the pre-eclampsia developed between 17-20 
years of age group and between 31-34 years, this correlates with the 
incidence of pre-eclampsia is more common with extremes of age as 
cited in many studying . 
Lehman analysed severe preeclampsia cases during 1970-1990 and 
found the incidence highest at extremes of child bear age. 
Therefore this study shows that extremes of age probably acts as one of 
the risk factors of developing pre-eclampsia. 
PARITY 
    Incidence of pre-eclampsia (17.4%) is high in primiparous women.  
This in concordance with reported incidence in India and western 
studies, showing and incidence of 16% in nullipara and 7% in 
multipara.          
Also 75%developed preeclampsia are primi and 25% are multi. 
In Parkland patients 70% were primi. Sibai and colleagues (1995) 
confirmed the higher risk of developing hypertension in the first 
pregnancy. 
SOCIO ECONOMIC STATUS            
     Preclampsia is common in low-socio economic group than high socio-
economic group., since most of patients in RSRM belonged only to low  
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socio-economic group, a comparison could not be done between socio-
economic groups in this study, 
OBESITY 
     Also pre-eclampsia is high(20%) in patients with high body mass 
index (>25).  This study showing high pre-eclampsia incidence with high 
BMI in concordance with many other reported studies in 
India.Walker(2000) study shows that ai incidence of 13.3% in those with 
a BMI >30.  
 BHCG ESTIMATION 
      22 patients out of 146 had BHCG > 2 MOM out of which 18 
developed pre-eclampsia and remaining 4 did not develop pre-eclampsia. 
Sensitivity being 90%, Specificity 96.8%. the Positive predictive value 
81.8%, Negative predictive value 98.4%. 
ODDS ratio, 274   P= < 0.001 (using chisquare yates correction) 
 The tables given below compare the sensitivity, specificity, positive and negative predictive value of 
BHCG with other studies. 
 
Author Year No.of 
Patients 
Parity Pre-
eclampsia 
incidence 
Sensiti
vity 
Specifi
city 
PPV  NPV 
Pankaj desai  
et al 
(1995-
2000) 
220 Both multi 
and primi 
16.15% 71% 65% 40 95 
Luckas 
et al 
1998 430 Primi 13.5% 80% 90% 75% 90% 
Roiz 
Hernandez 
et al 
2006 784 Both multi 
Primi 
12% 92% 92% 46 98% 
Present study 2009 
oct_ 
2010 oct 
150 Both multi 
primi 
13.6% 90% 96.8% 81.8% 98.4% 
 
  
 
This table shows comparing the sensitivity, specificity and positive and negative predictive value of roll 
over test with others study. 
 
Author Year No.of 
Patients 
Parity Pre-
eclampsi
a 
incidence 
Sensiti
vity 
Specific
ity 
PPV NPV 
Gant et al 1974 438 Primi 5.8% 80% 90% 33% 90% 
Narvaez et al 1988 782 Primi 8.10% 70% 95% 88% 92.5% 
Present 
study 
2009 oct to 
2010 oct 
150 Both multi 
primi 
13.6% 70% 86.6% 50% 94% 
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BHCG ESTIMATION   
 The sensitivity(90%) and specificity(96.8%) of our present study were 
similar to the study of Roiz Hernandez et al (2006). 
 The PPV of the study was similar to Luckas et al. 
The NPV was similar to Pankaj desai et al (1995-2000),Roiz Hernandez et 
al(2006). 
Also BHCG has high predictictability for primi para preeclampsia(100%) 
than multi(60%)This is similar to Francoise muller et al(1996). 
BHCG is highly valuable for early onset preeclampsia(75%).This was 
similar to the study of Sayeed et el-80%(1995).But roll over predicts only 
(25%) of cases. 
Also BHCG predicts 100% cases of severe preeclampsia with IUGR.This 
is similar to L.S.Ondero et al study (1997). 
ROLL OVER TEST 
 
28of 146 patients had roll test positive.But 14 only developed 
preeclampsia,with  sensitivity 70%,specificity 86.6%,PPV 
50%,NPV94%.ODDS RATIO 15.Pvalue<0.01(using chi square Yates 
correction). 
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The sensitivity of the test is similar to the Narvaez et al.(1998) 
 The specificity is simslar to Gant et al(1994) study.  
The NPV of the study is similar to Narvaez et al(1988).  
Roll over test is a simple test to perform,but having high sensitivity 
specificity,NPV.  
But it has some flaws. Some patients have unusually low diastolic 
pressure in the left lateral position,thus creating a false positive results 
when compared with the reading in the supine position. 
An artifact arises when the patient rolls from the left lateral 
position to ths supine position, as the position of the 
sphygmomanometer cuff relative to heart altered. 
Inter observer variation and poor reproducibility are the other 
disadvantages. 
 
 
SUMMARY 
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SUMMARY 
 
Following conclusions are drawn from the study. 
 
1.The present study compared BHCG elevation in comparison to roll over 
test among 150 asymptomatic pregnant women. 
2.  The incidence of pre-eclampsia in the study is 13.6%. 
3.Primiparity was found to be significant risk factor. 
4.High body mass index, extremes of age (i.e) <20 years and >30 years 
are associated with increased risk of developing pre-eclampsia. 
5.BHCG >2 MOM found in 22 persons among which 18persons 
developed pre-eclampsia. Sensitivity 90% specificity 96.8%, positive 
predictive value 81.8%, Negative predictive value 98.4%, ODDS ratio 274 
and P<0.001. 
6.A pregnant woman with multiparity or extremes of age or with high. 
7.Body mass index along with raised BHCG is at a high risk for 
development preeclampsia. 
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8.Also early onset preeclampsia <28 weeks, severe pre-eclampsia with 
IUGR are predicted by BHCG estimation with sensitivity of 75% and 
100% respectively. 
9.Also predicting primipara pre-eclampsia by BHCG is more(100%) than 
predicting multipara pre-eclampsia. 
10.Roll over test found positive in 28 persons among which 14 persons 
developed pre-eclampsia. Sensitivity 70%, specificity 86.6%, positive 
predictive value 50%, negative predictive value 94% OPPs ratio 15 and P 
<0.01. 
11.Due to some technical errors, roll over tests shows high false positive 
results. 
CONCLUSION 
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CONCLUSION 
1.The study shows that BHCG>2 MOM in early second trimester is 
an excellent screening tool for the prediction of pre-eclampsia with 
sensitivity of 90% and specificity of 96.8% , positive predictive value of 
81.8%, Negative predictive value of 98.4%. 
 
2. This test is ideal because it is now a days readily available, 
relatively cheap, cost effective, safe, easy to perform, readily 
interpretable.   
 
3. It has a good predictive value especially for early onset pre-
eclampsia and severe pre-eclampsia with IUGR which are said to have 
poor progmosis . 
 
      4. A primi para of extremes of age group with high body mass index 
with a high BHCG is especially at a high risk for development of pre-
eclampsia. 
5. In our study BHCG >2MOM is a better predictor than roll over test for 
preeclampsia.  
PROFORMA  
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PROFORMA 
NAME:                     AGE:     OP NO: 
ADDRESS:              REG NO: 
SOCIO ECONOMIC STATUS:           DATE: 
GRAVIDA     PARA                     ABORTION 
LIVE BIRTH 
LMP 
EDD 
MENSTRUAL HISTORY 
MARITAL HISTORY 
MEDICAL HISTORY 
       DIABETES 
       HYPERTENSION 
       EPILEPSY 
       RENAL DISEASE 
      HEART DISEASE    
PAST OBSTETRIC HISTORY:- 
      H/O STILL BIRTHS 
      ABRUPTION 
      RECURRENT ABORTIONS 
      GESTATIONAL HYPERTENSION 
FAMILY HISTORY:- 
      DIABETES 
      HYPERTENSION 
      GESTATIONAL HYPERTENSION 
      TWINS 
      CONGENITAL ANOMALIES 
ON GENERAL EXAMINATION 
PATIENT 
- BUILT 
- TEMPERATURE 
- ANEMIA 
- PULSERATE 
- BLOOD PRESSURE AT SITTING POSTURE 
- PEDAL EDEMA 
- HEIGHT 
- WEIGHT 
- BREAST 
- THYROID  
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            CVS 
            RS 
PER ABDOMEN 
       FUNDAL HEIGHT  
       WHETHER ACTING OR NOT 
INVESTICATIONS: 
        HB% 
        URINE – ALBUMIN 
                       SUGAR 
        BLOOD – SUGAR 
- HIV 
- BLOOD GROUPING 
- BLOOD FOR BHCG ESTIMATION 
       (Between 16-20 weeks) 
- ROLL  OVER TEST 
       (Between 18-22 weeks) 
- ULTRA SOUND 
- Ist TRIMESTER       IInd TRIMESTER      IIIrd TRIMESTER 
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FOLLOW UP 
 
 Specific 
Symptoms 
Weight Pedal 
Edema 
Blood 
Pressure 
Urine 
Protein 
P/A USG 
Findings 
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ABBREVIATIONS 
 ABBREVIATIONS 
 
Sflt-1 - Serum fms like tyrosine Kinase receptor -1  
IU/L   - International Units / Litre  
BHCG  - Beta human chorionic gonadotrophin  
PPV   - Positive Predictive Value  
NPV   - Negative Predictive Value 
CRP   - C-reactive Protein  
PAPP-A  - Pregnancy associated placental Protein-A 
RFT   - Renal Function Tests 
LFT   - Liver Function Tests 
CBC   - Complete hemogram 
FKC   - Foetal Kick Chart 
AFI   - Amniotic fluid index  
MOM   - Multiples of Median 
HLA   - Human Leucocyte Antigen  
MTHFR  - Methylene tetra hydro folate reductase  
MASTER CHART 
MASTER CHART 
S.No Name OP.No Age S/E Obstetric 
status 
BMI BHCG Roll over 
test 
Remarks 
1. Malini 11776 19 V Primi 23 < 2 MOM Negative  
2. Priya 11706 21 V Primi 22 < 2 MOM Positive  
3. Punitha 10766 17 V G2P1L1 22 > 2 MOM Positive  
4. Angammal 11780 20 V Primi 25 > 2 MOM Positive  
5. Syednisha 10788 22 V Primi 28 < 2 MOM Negative Developed Mild Pre-eclampsia 
6. Akila 10700 24 V G2P1L1 25 < 2 MOM Negative  
7. Tamilarasi 10005 25 V G2P1L1 27 > 2 MOM Positive Developed Mild Pre-eclampsia 
8. Indhira 2881 34 V Primi 29 > 2 MOM Positive Developed early onset pre-eclampsia 
9. Gowri 2851 28 V G2P1L1 30 < 2 MOM Negative  
10. Rangalakshmi 3678 20 V Primi 26 < 2 MOM Negative  
11. Vijaya 3679 27 V Primi 25 < 2 MOM Negative  
12. Devi 6509 26 V Primi 26 > 2 MOM Positive Developed Mild Pre-eclampsia 
13. Lakshmi.K 6016 28 V Primi 25 < 2 MOM Negative  
14. Vidhya 6210 25 V Primi 25 < 2 MOM Negative  
15. Mahadevi 12140 20 V Primi 27 > 2 MOM Positive Developed Mild Pre-eclampsia 
16. Maya 2820 26 V Primi 24 < 2 MOM Negative  
17. Hashish 2888 31 V Primi 23 < 2 MOM Negative  
18. Vanaja 11920 18 V G2P1L1 24 > 2 MOM Positive Developed Mild Pre-eclampsia 
19. Lakshmi. 10906 27 V G2P1L1 23 < 2 MOM Negative  
20 Shanthi 8455 25 V G2P1L1 24 < 2 MOM Negative  
 
S.No Name OP.No Age S/E Obstetric 
status 
BMI BHCG Roll over 
test 
Remarks 
21. Sheela 8655 27 V G2P1L1 25 < 2 MOM Negative  
22. Thenmozhi 8771  V G3P2L2 24 < 2 MOM Positive  
23. Yasoda 8661  V G3P2L2 22 < 2 MOM Positive  
24. Jayashree 9553  V Primi 25 < 2 MOM Positive  
25. Dhanam 9672  V Primi 22 < 2 MOM Negative  
26. Madhamma 2372  V Primi 26 < 2 MOM Negative  
27. Latha 6320  V G2P1L1 23 < 2 MOM Positive  
28. Rengaal 6000  V Primi 21 < 2 MOM Negative  
29. Erulaaya 321  V Primi 21 < 2 MOM Negative  
30. Janagi 6307  V G2P1L1 27 < 2 MOM Negative  
31. Parveen 6352  V G2P1L1 25 < 2 MOM Negative  
32. Selvi 3321  V G2P1L1 27 < 2 MOM Negative  
33. Hemalatha 5005  V Primi 23 < 2 MOM Negative  
34. Ramadevi 11672 26 V Primi 24 < 2 MOM Negative  
35. Varalakshi 11680 28 V Primi 23 < 2 MOM Negative  
36. Saseekala 11075 29 V Primi 22 < 2 MOM Negative  
37. Amsha 11680 30 V Primi 25 < 2 MOM Positive  
38. Usha 11673 32 V G2P1L1 26 < 2 MOM Negative  
39. Kalaivani 11688 24 V G2P1L1 20 < 2 MOM Positive  
40. Rukku 11700 22 V G3P2L2 21 < 2 MOM Negative  
 
 S.No Name OP.No Age S/E Obstetric 
status 
BMI BHCG Roll over 
test 
Remarks 
41. Saradha 11750 25 V G2P1L1 23 < 2 MOM Negative  
42. Sarawathi 11850 23 V G2P1L1 29 < 2 MOM Negative  
43. Poongodi 11860 31 V Primi 30 < 2 MOM Negative  
44. Maheswari 13321 28 V Primi 23 > 2 MOM Negative  
45. Nandhini 2321 33 V G2P1L1 32 < 2 MOM Negative  
46. Kavitha 7252 26 V Primi 34 > 2 MOM Positive Developed Mild Pre-eclampsia 
47. Violet  30 V G2P1L1 30 < 2 MOM Negative  
48. Mohana 7777  V Primi 26 > 2 MOM Positive Developed Mild Pre-eclampsia 
49. Nirmala 1673 27 V Primi 24 < 2 MOM Negative  
50. Lurthumary 1688 30 IV G2P1L1 25 < 2 MOM Negative  
51. Sulthana 1781 33 V G2P1L1 28 < 2 MOM Negative  
52. Rajeswari 1785 31 V G2P1L1 28 < 2 MOM Negative  
53. Rajini 1882 27 V G3P2L2 26 < 2 MOM Negative  
54. Shripriya 1990 26 V G4P2L1A1 22 < 2 MOM Positive  
55. Bharathi 2232 27 V Primi 25 > 2 MOM Negative  
56. Deivanai 2588 25 IV Primi 25 < 2 MOM Negative  
57. Fathima 2001 28 IV Primi 21 < 2 MOM Negative  
58. Shahitha 2090 29 IV Primi 20 < 2 MOM Positive  
59. Mehapoob 2098 28 IV Primi 27 < 2 MOM Negative  
60. Sulochana 10850 29 IV Primi 27 < 2 MOM Negative  
 
 
 S.No Name OP.No Age S/E Obstetric 
status 
BMI BHCG Roll over 
test 
Remarks 
61. Ramamani 6667 19 IV Primi 27 > 2 MOM Positive Developed Mild Pre-eclampsia 
62. Manpreeth 4231 30 IV Primi 28 < 2 MOM Negative  
63. Nirmala 4561 30 V G2P1L1 29 < 2 MOM Negative  
64. Lilli 4451 18 V G2P1L1 30 < 2 MOM Negative  
65. Annalakshi 4621 18 V G2P1L1 31 < 2 MOM Negative  
66. Parvathi 12001 18 V Primi 27 < 2 MOM Negative  
67. SagayaMary 12012 19 V Primi 26 < 2 MOM Negative  
68. Usha Samuvel 12017 21 V G2P1L1 26 < 2 MOM Negative  
69. Anitha 12064 19 V G2P1L1 24 < 2 MOM Negative  
70. Sangeetha 12100 30 V Primi 22 < 2 MOM Negative  
71. Saranya 12085 24 V G2P1L1 20 < 2 MOM Negative  
72. Kumutha 12088 22 V Primi 20 < 2 MOM Negative  
73. Ethar 12093 21 V Primi 18 < 2 MOM Negative  
74. Zinath 12201 19 V Primi 25 < 2 MOM Negative  
75. Ponamani 12204 19 V G3P1A1 25 < 2 MOM Positive  
76. Jebaselvi 12260 17 V G2P1L1 27 < 2 MOM Negative  
77. Velanganni 12268 17 V G2P1L1 27 < 2 MOM Negative  
78. Ayishabanu 13078 18 V Primi 24 < 2 MOM Negative  
79. Samshath 8878 27 V Primi 27 < 2 MOM Negative  
80. Nalayini 8890 28 V Primi 22 < 2 MOM Negative  
 
 
S.No Name OP.No Age S/E Obstetric 
status 
BMI BHCG Roll over 
test 
Remarks 
81. Manimehalai 8320 33 V Primi 22 < 2 MOM Negative  
82. Koushalya 8991 23 V Primi 29 < 2 MOM Negative  
83. Kuppu 8995 20 V Primi 28 < 2 MOM Negative  
84. Dharani 6121 24 V Primi 31 > 2 MOM Negative Developed early onset pre-eclampsia 
85. Kannmani 8890 34 V Primi 29 < 2 MOM Negative  
86. Ananthi 9025 21 V G3P1A1 27 < 2 MOM Negative  
87. Kowsor 9028 25 V Primi 24 < 2 MOM Positive  
88. Sudha 9063 25 V Primi 25 < 2 MOM Negative  
89. Ramya 9960 26 IV Primi 24 < 2 MOM Positive  
90. Shoba 9265 26 IV Primi 23 < 2 MOM Negative  
91. Shophia 9385 29 IV Primi 29 < 2 MOM Negative Developed Mild Pre-eclampsia 
92. Govindhammal 6127 22 IV G3P2L2 24 > 2 MOM Negative  
93. Marypunitha 9388 30 IV Primi 21 < 2 MOM Negative  
94. Chellammal 9408 32 IV Primi 26 < 2 MOM Negative  
95. Roshini 9510 30 IV Primi  > 2 MOM Negative  
96. Dheepu 12230 18 IV Primi 32 > 2 MOM Positive Developed early onset pre-eclampsia 
97. Muniammal 9660 31 IV Primi 27 < 2 MOM Negative  
98. Kannammal 9638 23 IV Primi 27 < 2 MOM Negative  
99. Vaheetha 8321 21 V Primi 25 < 2 MOM Negative  
100. Vijayalakshmi 8327 24 V Primi 24 < 2 MOM Negative  
 
 S.No Name OP.No Age S/E Obstetric 
status 
BMI BHCG Roll over 
test 
Remarks 
101. Yamuna 8330 17 V Primi 23 < 2 MOM Negative  
102. Thavamani 8419 17 V Primi 23 < 2 MOM Negative  
103. Menaha 8420 18 V G2P1L1 20 < 2 MOM Positive  
104. Alamelu 8505 20 V Primi 21 < 2 MOM Negative  
105. Roopavathi 8507 21 V Primi 27 < 2 MOM Negative  
106. Alphonsa 6531 33 V Primi 28 > 2 MOM Negative Developed severe Pre-eclampsia with IUGR 
107. Vasuki 8003 23 V Primi 27 < 2 MOM Negative  
108. Periyamma 8590 23 V G3P2L2 26 < 2 MOM Negative  
109. Jothi 8661 25 V Primi 25 > 2 MOM Negative Developed Mild Pre-eclampsia 
110. Sapna 8708 25 V Primi 24 < 2 MOM Negative  
111. Reshma 8503 27 V Primi 23 < 2 MOM Negative  
112. Jeevitha 8888 30 V Primi 23 < 2 MOM Negative  
113. Geetha 6101 30 IV Primi 24 < 2 MOM Negative  
114. Sudarmani 5217 29 V Primi 23 < 2 MOM Negative  
115. RejinaMary 6555 31 IV G2P1L1 32 > 2 MOM Positive Developed Mild Pre-eclampsia 
116. Ranjitha 5333 27 V Primi 24 < 2 MOM Negative  
117. Manonmani 5389 23 V Primi 21 < 2 MOM Negative  
118. Muthukumari 5390 25 V Primi 21 < 2 MOM Negative  
119. Shree 5399 22 V Primi 20 < 2 MOM Negative  
120. Velammal 2332 34 IV Primi 29 > 2 MOM Negative Developed severe Pre-eclampsia with IUGR 
 
 S.No Name OP.No Age S/E Obstetric 
status 
BMI BHCG Roll over 
test 
Remarks 
121. SelvaMary 6010 21 V Primi 25 < 2 MOM Negative  
122. Nagajothi 6111 19 V Primi 20 < 2 MOM Negative  
123. Suganya 6212 19 V Primi 20 < 2 MOM Negative  
124. Pradeepa 12111 24 V Primi 23 > 2 MOM Negative Developed Mild Pre-eclampsia 
125. Malathi 6236 17 V Primi 20 < 2 MOM Negative  
126. Subha 6337 23 V Primi 21 < 2 MOM Negative  
127. Nithya 6837 18 V Primi 21 < 2 MOM Negative  
128. Yogalakshmi 6890 18 V G2P1L1 21 < 2 MOM Negative  
129. Ramani 7110 21 V G2P1L1 29 < 2 MOM Negative  
130. Sonali 7029 27 V Primi 26 < 2 MOM Negative  
131. Preethi Kour 2916 21 V Primi 22 < 2 MOM Negative  
132. Priyanka 2902 32 V G2P1L1 26 > 2 MOM Positive Developed Mild Pre-eclampsia 
133. Ishwarya 2920 20 V Primi 24 < 2 MOM Negative  
134. Ponni 3020 22 V G2P1L1 23 < 2 MOM Negative  
135. Sarala 3221 21 V Primi 21 < 2 MOM Positive Developed Mild Pre-eclampsia 
136. Yeswathbegam 3226 21 V Primi 21 < 2 MOM Negative  
137. Chitra 3418 33 IV Primi 26 < 2 MOM Negative  
138. Fathima 3510 32 IV G2P1L1 28 < 2 MOM Negative  
139. Hemavathi 6363 20 IV Primi 26 > 2 MOM Positive Developed early onset Pre-eclampsia &  IUGR 
140. Zarena 3030 22 IV Primi 25 < 2 MOM Negative  
 
 S.No Name OP.No Age S/E Obstetric 
status 
BMI BHCG Roll over 
test 
Remarks 
141. Vijayarani 3552 32 IV G2A1 25 < 2 MOM Negative  
142. Masthani 2319 32 IV Primi 25 > 2 MOM Negative  
143. Radhika 3555 23 IV G2A1 25 < 2 MOM Negative  
144. Vimala 8120 21 IV Primi 24 < 2 MOM Negative  
145. Parimala 8005 28 IV Primi 24 < 2 MOM Negative  
146. Nazimunisha 8017 25 IV G2A1 24 < 2 MOM Negative  
147. Malar 8018 26 IV G2P1L1 24 > 2 MOM Negative Developed GDM 
148. Sujatha 8111 22 IV G2P1L1 24 < 2 MOM Negative Non compliant 
149. Jaya 8330 32 V Primi 22 < 2 MOM Negative Developed GDM 
150. Subhathra 8342 34 V Primi 23 < 2 MOM Negative Non compliant 
 
 
 
 
ABBREVIATIONS 
GDM  - Gestational diabetes mellitus 
OP No - Out patient number 
S/E  - Socio-economic status 
S.No  - Serial Number 
G2P1L1 - Gravida 1 Para 1 Live 1 
G2A1  - Gravida 2 Abortion 1 
G3P2L2 - Gravida 3 Para 2 Live 2 
G4P2A1 - Gravida 4 Para 2 Abortion 1 
 
 
 
